- Home
- JEQ vs PLRX Comparison
JEQ vs PLRX Comparison
Compare JEQ & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEQ
- PLRX
- Stock Information
- Founded
- JEQ 1990
- PLRX 2015
- Country
- JEQ United States
- PLRX United States
- Employees
- JEQ N/A
- PLRX N/A
- Industry
- JEQ Air Freight/Delivery Services
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- JEQ Consumer Discretionary
- PLRX Health Care
- Exchange
- JEQ Nasdaq
- PLRX Nasdaq
- Market Cap
- JEQ 99.8M
- PLRX 84.7M
- IPO Year
- JEQ N/A
- PLRX 2020
- Fundamental
- Price
- JEQ $7.51
- PLRX $1.20
- Analyst Decision
- JEQ
- PLRX Hold
- Analyst Count
- JEQ 0
- PLRX 10
- Target Price
- JEQ N/A
- PLRX $9.79
- AVG Volume (30 Days)
- JEQ 32.0K
- PLRX 1.5M
- Earning Date
- JEQ 01-01-0001
- PLRX 08-06-2025
- Dividend Yield
- JEQ 7.05%
- PLRX N/A
- EPS Growth
- JEQ N/A
- PLRX N/A
- EPS
- JEQ N/A
- PLRX N/A
- Revenue
- JEQ N/A
- PLRX N/A
- Revenue This Year
- JEQ N/A
- PLRX N/A
- Revenue Next Year
- JEQ N/A
- PLRX N/A
- P/E Ratio
- JEQ N/A
- PLRX N/A
- Revenue Growth
- JEQ N/A
- PLRX N/A
- 52 Week Low
- JEQ $4.99
- PLRX $1.10
- 52 Week High
- JEQ $6.39
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- JEQ 68.54
- PLRX 34.60
- Support Level
- JEQ $6.94
- PLRX $1.23
- Resistance Level
- JEQ $7.62
- PLRX $1.43
- Average True Range (ATR)
- JEQ 0.14
- PLRX 0.11
- MACD
- JEQ 0.02
- PLRX -0.02
- Stochastic Oscillator
- JEQ 64.52
- PLRX 8.33
About JEQ abrdn Japan Equity Fund Inc.
Aberdeen Japan Equity Fund Inc is a United States-based closed-end diversified management investment company. Its investment objective is to outperform over the long term, on a total return basis (including appreciation and dividends), the Tokyo Stock Price Index ("TOPIX"). The fund seeks to achieve its investment objective by investing a majority of its assets, in equity securities of companies listed on the Tokyo Stock Exchange or listed on the over-the-counter market in Japan or listed on other stock exchanges in Japan. The portfolio of investments is spread across Consumer Discretionary, Industrials, Information Technology, Financials, and other sectors.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.